Penn Faculty Weighs in On the Future of American Science
John Wherry, PhD, the Richard and Barbara Schiffrin President's Distinguished Professor at Penn Medicine, explains how decades of federal funding for basic science enabled breakthroughs.
Penn Partners in New National Science Foundation AI Institute for Human-AI Cooperation
The institute will bring together more than 40 partners across academia, industry, government, healthcare, and nonprofit organizations to transform the role of AI in healthcare.
PA State Budget Passes with $125 million Investment in Pennsylvania’s Life Sciences Industry
The budget includes the Innovate in PA 2.0 Program, which will provide capital for startups, fund clinical trials for life sciences and improve the Commonwealth's innovation network.
CAR T Cell Therapy for Lymphoma Leads to 10 Year Remissions for Patients
The follow-up study of patients ten years later showed promising results.
ARPA-H Awards $43 million to Philadelphia Gene Therapy Researchers to Advance Rare Disease Treatments
Learn more about the recipients.
BioAdvance Capital Invests in Penn Life Sciences Startups
These investments will support the startups in further developing their treatments and technologies.
Network Bio Launches with $50 million in Funding to Create a Research Network of Large Biobanks to Drive AI Medical Research
Several U.S. Academic Medical Centers, including Penn Medicine, have partnered with Network Bio to generate large-scale multi-omic and multi-modal datasets.
Dispatch Bio Initiates Clinical Trials for a New Type of Cancer Treatment
The technology is intended to overcome a key limitation of current CAR-T cell therapies by broadening the range of tumors that can be targeted and treated.
Veradermics Reports First Positive Efficacy in Women for Hair Loss Treatment
Veradermics reported positive results for its oral formulation of minoxidil to treat female pattern hair loss.
Biogen Reports Early Success from Apellis Acquisition
Since Biogen’s acquisition of Apellis in May 2026, the company’s C3 complement therapies, Syfovre® and Empaveli®, have generated a combined $128 million in revenues.